Stockreport

Tango Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Highlights [Yahoo! Finance]

Erasca, Inc.  (ERAS) 
PDF New clinical supply agreement with Erasca, plus ongoing Revolution Medicines collaboration, supports potential of vopimetostat as the preferred PRMT5 inhibitor for comb [Read more]